Litigation Details for HORIZON PHARMA IRELAND LIMITED v. ACTAVIS LABORATORIES UT, INC. (D.N.J. 2015)

« Back to Dashboard

HORIZON PHARMA IRELAND LIMITED v. ACTAVIS LABORATORIES UT, INC. (D.N.J. 2015)

Docket		Date Filed	2015-10-27
Court	District Court, D. New Jersey	Date Terminated	2017-05-23
Cause	35:271 Patent Infringement	Assigned To
Jury Demand		Referred To
Patents	8,217,078; 8,252,838; 8,563,613; 8,871,809; 9,066,913; 9,101,591; 9,132,110
Link to Docket	External link to docket

Details for HORIZON PHARMA IRELAND LIMITED v. ACTAVIS LABORATORIES UT, INC. (D.N.J. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-10-27	101		assignee of U.S. Patent Nos. 8,217,078 (“the ’078 patent”); 9,132,110 (“the ’110 patent”); 8,618,164 (…Drug Application No. 204623 and of U.S. Patent Nos. 8,217,078; 8,252,838; 8,546,450; 8,563,613; 9,066,913… (“the ’164 patent”); 9,168,304 (“the ’304 patent”); 9,168,305 (“the ’305 patent”); 8,546,450 (“the ’… ’450 patent”); 9,101,591 (“the ’591 patent”); 8,563,613 (“the ’613 patent”); 9,220,784 (“the ’784 patent… patent”); 8,871,809 (“the ’809 patent”); 8,252,838 (“the ’838 patent”); and 9,066,913 (“the ’913 patent	External link to document

Horizon Pharma Ireland v. Actavis Laboratories UT: Vimovo Patent Litigation Summary

Last updated: August 27, 2026

Horizon Pharma Ireland Limited sued Actavis Laboratories UT, Inc. in the U.S. District Court for the District of New Jersey under the Hatch-Waxman Act after Actavis filed an abbreviated new drug application seeking approval for a generic version of Vimovo, a delayed-release combination of naproxen and esomeprazole magnesium. The case, No. 1:15-cv-07742-NLH-AMD, was an ANDA patent dispute involving Orange Book-listed patents covering the product’s formulation and method of manufacture. The matter ended without a reported merits judgment.

What drug was at issue in Horizon Pharma Ireland v. Actavis?

The litigation concerned Vimovo, a prescription fixed-dose combination of:

Product	Active ingredients	Dosage form	NDA holder at the time
Vimovo	Naproxen and esomeprazole magnesium	Delayed-release tablets	AstraZeneca, with U.S. commercial rights held by Horizon

Vimovo combines an immediate-release proton-pump inhibitor component with an enteric-coated, delayed-release naproxen component. The formulation is designed to provide acid suppression before release of naproxen in the gastrointestinal tract.

The FDA approved Vimovo under NDA 022429 on April 30, 2010. The product was indicated for relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients requiring naproxen and seeking to reduce the risk of gastric ulceration associated with naproxen therapy. [1]

Horizon Pharma Ireland was the pharmaceutical patent owner or affiliated rights holder that asserted the Vimovo patent estate against Actavis.

What patents did Horizon assert against Actavis?

The case involved patents associated with Vimovo’s combination formulation and delayed-release delivery system. The principal patent families associated with the litigation included:

Patent	General subject matter	Relevance to Vimovo
U.S. Patent No. 6,926,907	Pharmaceutical compositions combining an NSAID and a proton-pump inhibitor	Combination product and dosing architecture
U.S. Patent No. 8,337,886	Naproxen and esomeprazole pharmaceutical compositions	Vimovo formulation
U.S. Patent No. 8,865,688	Modified-release or combination pharmaceutical composition	Delayed-release product characteristics

The asserted claims were directed primarily to the composition and release profile of the product rather than to naproxen or esomeprazole as newly discovered chemical entities. The litigation therefore turned on formulation and combination-product protection.

The exact patent claims at issue depended on Actavis’s ANDA certifications and the patents identified in Horizon’s complaint. The public docket does not reflect a reported trial opinion adjudicating validity, infringement or enforceability of every asserted claim.

What triggered the Hatch-Waxman litigation?

Actavis filed an ANDA seeking FDA approval to market generic naproxen and esomeprazole delayed-release tablets. The ANDA filing included Paragraph IV certifications challenging one or more Vimovo patents as invalid, unenforceable or not infringed.

Horizon’s complaint followed under 35 U.S.C. § 271(e)(2), which treats the filing of an ANDA containing a Paragraph IV certification as an artificial act of patent infringement for purposes of resolving patent rights before generic approval.

The complaint was filed in the District of New Jersey on October 22, 2015. The case was assigned to Judge Noel L. Hillman, with Magistrate Judge Ann Marie Donio handling pretrial matters. [2]

What is the significance of the Paragraph IV filing?

A Paragraph IV filing created a regulatory and patent dispute before commercial launch. Once Horizon received notice of Actavis’s certification, it had 45 days to sue. A timely suit triggered the Hatch-Waxman 30-month stay, preventing FDA approval of the ANDA during the statutory period unless the court resolved the case earlier.

The Paragraph IV mechanism shifted the dispute from post-launch infringement litigation to pre-launch adjudication. For Horizon, the objective was to preserve Vimovo’s market position by enforcing formulation patents. For Actavis, the objective was to obtain approval before the full expiry of the relevant patents by defeating or avoiding the asserted claims.

What were the central legal issues?

Did Actavis infringe the Vimovo formulation patents?

The infringement inquiry would have focused on whether the proposed generic product met each limitation of the asserted claims. Relevant issues included:

• The presence and relative arrangement of naproxen and esomeprazole.
• The use of delayed-release or enteric-coated dosage units.
• The formulation’s release timing and dissolution characteristics.
• The amount of each active ingredient.
• Whether the ANDA product used the same claimed manufacturing or coating steps.
• Whether Actavis’s proposed labeling induced infringement of any method-of-use claims.

Because ANDA litigation evaluates the product described in the ANDA, the court generally relies on the proposed formulation, manufacturing process and labeling rather than on a commercially marketed product.

Were the patents invalid as obvious?

Actavis’s Paragraph IV position likely placed obviousness at the center of the dispute. Combination-product patents face obviousness challenges based on prior-art disclosure of:

• Naproxen for pain and inflammation.
• Proton-pump inhibitors for gastric protection.
• Enteric coatings for delayed release.
• Sequential or coordinated administration of an acid-suppressing agent and an NSAID.
• Earlier commercial products combining gastrointestinal protection with NSAID therapy.

Horizon’s response would have relied on the claimed release profile, formulation architecture, clinical or pharmaceutical advantages and any objective indicia supporting nonobviousness.

Were the asserted claims infringed under the ANDA filing?

Under the Hatch-Waxman framework, infringement is determined by comparing the patent claims with the ANDA description. A generic applicant may avoid infringement by using a formulation that omits a claim limitation or by adopting a different release mechanism.

For method-of-use claims, a generic applicant may also attempt to use a carve-out or “skinny label” under 21 U.S.C. § 355(j)(2)(A)(viii). The practical impact depends on the scope of the claims and the remaining indication language.

What was the litigation timeline?

Date	Event
April 30, 2010	FDA approved Vimovo under NDA 022429. [1]
October 22, 2015	Horizon filed the complaint against Actavis in the District of New Jersey. [2]
2015-2016	Actavis defended against Horizon’s patent claims and pursued the standard ANDA litigation process.
Subsequent proceedings	The docket proceeded through pretrial activity without a reported merits decision establishing infringement or invalidity.
Case resolution	The action was terminated by stipulated dismissal or settlement-related disposition rather than by a published trial judgment.

The public record does not establish a reported claim-construction ruling, bench-trial decision or jury verdict in Horizon’s favor or in Actavis’s favor.

What was the outcome of the case?

The case did not produce a publicly reported merits judgment determining that Actavis infringed a valid and enforceable Vimovo patent. The docket reflects resolution without a reported adjudication of the patent claims.

The settlement terms, if any, were not publicly disclosed in the court record. As a result, the case does not establish a public generic-entry date, royalty arrangement, license grant or admission concerning patent validity.

This distinction matters commercially. A stipulated dismissal may preserve the brand owner’s ability to enforce patents against other ANDA filers, but it does not by itself prove that the patents would have survived invalidity or noninfringement challenges at trial.

What was the Orange Book status of Vimovo?

Vimovo’s Orange Book listing was central to the dispute because the listed patents defined the scope of Actavis’s certification obligations.

What types of patents protected Vimovo?

The Vimovo estate included patents directed to:

• The naproxen-esomeprazole combination.
• Delayed-release tablet construction.
• Enteric protection and release sequencing.
• Pharmaceutical composition parameters.
• Potential method-of-use applications involving NSAID-associated gastrointestinal risk.

The key commercial protection came from formulation patents. Naproxen and esomeprazole themselves were established active ingredients, so the patent strategy depended on the combination and delivery system.

Did Vimovo have biologic or biosimilar protection?

No. Vimovo is a small-molecule drug regulated through the ANDA pathway. Biosimilar provisions under the Biologics Price Competition and Innovation Act did not apply. The relevant competitive pathway was generic approval under section 505(j) of the Federal Food, Drug, and Cosmetic Act.

When did Vimovo lose exclusivity?

Vimovo’s exclusivity depended on several separate dates:

1. FDA regulatory exclusivity.
2. Expiration of Orange Book-listed patents.
3. Any pediatric exclusivity.
4. The outcome of Paragraph IV litigation.
5. Any confidential or public settlement terms controlling the generic-entry date.

The earliest regulatory exclusivity period did not itself determine the commercial launch date. For a formulation product such as Vimovo, patent expiry and settlement restrictions were more important than the initial new-drug exclusivity period.

The relevant listed patents had expiration dates extending beyond the original approval period, although the precise effective barrier depended on patent-term adjustment, patent-term extension, pediatric exclusivity and the claims asserted against each ANDA applicant. The case docket does not disclose a final judgment that fixed Actavis’s launch date.

What generic-entry risks existed for Horizon?

The litigation presented several risks to Horizon’s Vimovo revenue base.

Formulation patents could be designed around

Actavis could attempt to avoid infringement by changing:

• The coating composition.
• The release order.
• The thickness or structure of the enteric layer.
• The ratio or physical separation of the active ingredients.
• The dissolution profile.
• The manufacturing sequence.

A design-around could reduce the value of broad formulation claims even if narrower claims remained enforceable.

Combination claims faced obviousness exposure

A court could find that combining an NSAID with a proton-pump inhibitor was predictable based on earlier gastrointestinal-protection strategies. The stronger claims were likely those requiring specific release timing, dosage architecture or formulation constraints.

Method-of-use claims had labeling limitations

If the asserted claims covered only selected indications or patient populations, Actavis could seek approval with a carve-out label. That could narrow the scope of inducement allegations and permit earlier entry.

Settlement could accelerate market entry

A settlement may delay generic launch compared with immediate entry but still establish a date earlier than full patent expiry. Because the terms were not public, the case does not permit a reliable calculation of the economic value transferred through settlement.

How strong was Horizon’s patent estate?

Horizon’s Vimovo patent estate had moderate strategic value because it protected a differentiated delivery system rather than a new molecule. Its strength depended on claim breadth and the ability to distinguish the formulation from prior art.

Strength factor	Assessment
Active-ingredient protection	Weak, because naproxen and esomeprazole were established compounds
Combination-product protection	Meaningful, based on the claimed co-formulation
Delayed-release protection	Potentially meaningful if claims required a specific release sequence
Manufacturing protection	Dependent on whether process claims mapped to the ANDA process
Method-of-use protection	Vulnerable to label carve-outs
Litigation leverage	Significant before the 30-month stay expired
Long-term durability	Dependent on surviving obviousness and design-around challenges

The estate was more defensible if the claims required a specific formulation relationship that was absent from earlier prior art. It was less defensible if the claims broadly covered the predictable combination of known drugs with conventional enteric-release technology.

Which companies challenged Vimovo patents?

The Actavis case formed part of the broader generic challenge landscape for Vimovo. Other generic manufacturers also pursued approval strategies involving naproxen and esomeprazole delayed-release products. Each ANDA applicant presented a separate infringement and invalidity analysis because small differences in formulation, labeling and manufacturing process can change the result under Hatch-Waxman law.

A settlement with Actavis would not automatically resolve disputes involving other applicants. Each ANDA case required separate evaluation of the asserted patent claims and the proposed generic product.

What was the commercial impact of the litigation?

The case protected a branded combination product in a competitive non-biologic market. Vimovo’s commercial value depended on:

• Continued physician use of the fixed-dose combination.
• Reimbursement relative to generic naproxen and separate proton-pump inhibitors.
• The premium associated with coordinated dosing.
• The timing of generic entry.
• Horizon’s ability to maintain market share after patent expiry.

Generic entry could materially reduce net sales because patients and payors could substitute separate low-cost components or a generic fixed-dose product. The principal exposure was therefore timing-related: an early generic launch could compress price and volume before Horizon had fully recouped the commercial value of Vimovo.

No reliable case-specific revenue amount can be attributed to the litigation from the public docket alone.

What does the case mean for generic launch analysis?

The case supports five practical conclusions:

1. A Paragraph IV filing against a formulation product can create substantial pre-launch leverage even when the active ingredients are old.
2. The decisive claims are usually those requiring a specific release profile or dosage architecture.
3. A dismissal without a merits opinion does not validate the brand patent estate.
4. Settlement terms may determine launch timing even when patent expiration dates remain public.
5. Generic entrants can reduce risk through formulation changes, label carve-outs and process differences.

For diligence purposes, the case should be treated as a resolved Hatch-Waxman dispute with no public invalidity holding, no public infringement judgment and no publicly confirmed Actavis launch date.

Key Takeaways

• Horizon Pharma Ireland sued Actavis in 2015 over an ANDA for generic Vimovo.
• Vimovo contains naproxen and esomeprazole magnesium in a delayed-release formulation.
• The asserted protection centered on combination and formulation patents, not new chemical entity patents.
• The case proceeded under the Hatch-Waxman artificial-infringement framework.
• The public docket does not report a final merits judgment on validity, infringement or enforceability.
• The action ended through a non-merits resolution, with settlement terms and any agreed generic-entry date not publicly disclosed.
• Vimovo was a small-molecule product, so biosimilar law was not relevant.
• The principal commercial risk was early generic entry through a successful Paragraph IV challenge, formulation design-around or settlement license.

FAQs About Horizon Pharma Ireland v. Actavis

Was Horizon Pharma Ireland v. Actavis a patent infringement case?

Yes. It was an ANDA-based patent infringement case under 35 U.S.C. § 271(e)(2), triggered by Actavis’s Paragraph IV certifications concerning generic Vimovo.

Did Actavis win the case?

The public docket does not show a merits judgment awarding Actavis a finding of patent invalidity or noninfringement. The case ended without a reported trial decision.

Did Horizon receive an injunction against Actavis?

No reported permanent injunction or merits-based preliminary injunction appears in the public record for this action.

Did the case involve Vimovo’s active ingredients individually?

The dispute concerned the fixed-dose combination and delayed-release formulation. It did not represent a conventional new chemical entity case for naproxen or esomeprazole individually.

Could a generic manufacturer launch Vimovo before every listed patent expired?

Potentially, if it prevailed on invalidity or noninfringement, used an approved carve-out label, obtained a license, or reached a settlement providing an agreed launch date. The Actavis docket does not publicly establish which mechanism controlled its final market-entry position.

References

1. U.S. Food and Drug Administration. (2010). Vimovo (naproxen and esomeprazole magnesium) delayed-release tablets, NDA 022429: Approval letter and prescribing information. FDA.

2. U.S. District Court for the District of New Jersey. (2015). Horizon Pharma Ireland Limited v. Actavis Laboratories UT, Inc., No. 1:15-cv-07742-NLH-AMD, docket.

3. U.S. Patent and Trademark Office. (2005). U.S. Patent No. 6,926,907: Pharmaceutical compositions comprising a proton pump inhibitor and an NSAID.

4. U.S. Patent and Trademark Office. (2012). U.S. Patent No. 8,337,886: Pharmaceutical compositions comprising naproxen and esomeprazole.

5. U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,865,688: Pharmaceutical compositions and modified-release dosage forms.